Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxwell V Meng

Showing results (171-180 of 184) with videos related to

Pageof 19
Sort By:
Urology|December 5, 2020
Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical CystectomyCarissa E Chu, Lauren Law, Kyle Zuniga, et al.
JCI Insight|April 29, 2025
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancerSerena S Kwek, Hai Yang, Tony Li, et al.
Lancet Regional Health. Americas|March 9, 2026
Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019Kevin L'Espérance, Katherine Lin, Daphne Lichtensztajn, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2026
Functionally heterogeneous intratumoral CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells can give rise to single-positive T cellsTony Li, Arielle Ilano, Marcel Arias-Badia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Journal of Urology|October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study ComparisonsMeera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Frontiers in Surgery|October 21, 2022
A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyondJeffrey J Leow, Wei Shen Tan, Wei Phin Tan, et al.
Cell|June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Pageof 19

Showing results (171-180 of 184) with videos related to

Sort By:
Pageof 19
Urology|December 5, 2020
Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical CystectomyCarissa E Chu, Lauren Law, Kyle Zuniga, et al.
JCI Insight|April 29, 2025
Identification and regulation of circulating tumor-TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancerSerena S Kwek, Hai Yang, Tony Li, et al.
Lancet Regional Health. Americas|March 9, 2026
Renal cell carcinoma incidence and mortality in California: a population-based study of sociodemographic patterns and temporal trends from 1988 through 2019Kevin L'Espérance, Katherine Lin, Daphne Lichtensztajn, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 20, 2026
Functionally heterogeneous intratumoral CD4<sup>+</sup>CD8<sup>+</sup> double-positive T cells can give rise to single-positive T cellsTony Li, Arielle Ilano, Marcel Arias-Badia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
The Journal of Urology|October 25, 2021
Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study ComparisonsMeera R Chappidi, Heiko Yang, Maxwell V Meng, et al.
Nature Communications|June 17, 2025
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expressionHeiko Yang, Hanbing Song, Elizabeth Yip, et al.
Frontiers in Surgery|October 21, 2022
A systematic review and meta-analysis on delaying surgery for urothelial carcinoma of bladder and upper tract urothelial carcinoma: Implications for the COVID19 pandemic and beyondJeffrey J Leow, Wei Shen Tan, Wei Phin Tan, et al.
Cell|June 5, 2020
Intratumoral CD4<sup>+</sup> T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder CancerDavid Y Oh, Serena S Kwek, Siddharth S Raju, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Pageof 19